NCT00657813View on ClinicalTrials.gov

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

MNI-330 as a brain SPECT tracer of Beta-Amyloid

Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

Sponsors

Collaborators (1)

Molecular NeuroImaging
All Listed Sponsors
collaborator

Molecular NeuroImaging

OTHER

lead

Institute for Neurodegenerative Disorders

OTHER